Analyst Price Targets — BLCO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 23, 2026 1:27 pm | — | H.C. Wainwright | $20.00 | $17.64 | TheFly | Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright |
| February 19, 2026 12:24 pm | — | Stifel Nicolaus | $16.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $16 from $15 at Stifel |
| February 19, 2026 12:23 pm | — | Deutsche Bank | $18.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank |
| February 19, 2026 11:29 am | — | Barclays | $20.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $20 from $17 at Barclays |
| February 17, 2026 1:04 pm | — | Stifel Nicolaus | $15.00 | $17.25 | TheFly | Bausch + Lomb price target raised to $15 from $14 at Stifel |
| January 27, 2026 12:53 pm | — | RBC Capital | $21.00 | $16.87 | TheFly | Bausch + Lomb price target raised to $21 from $19 at RBC Capital |
| January 9, 2026 10:49 am | David Roman | Goldman Sachs | $19.00 | $17.30 | TheFly | Bausch + Lomb price target raised to $19 from $17 at Goldman Sachs |
| January 5, 2026 11:20 am | Vijay Kumar | Evercore ISI | $18.00 | $16.58 | TheFly | Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI |
| December 2, 2025 11:24 am | — | Morgan Stanley | $21.00 | $16.56 | TheFly | Bausch + Lomb upgraded to Overweight at Morgan Stanley on pipeline potential |
| November 14, 2025 9:30 am | Douglas Miehm | RBC Capital | $19.00 | $15.69 | StreetInsider | Bausch & Lomb Corp. (BLCO) PT Raised to $19 at RBC Capital |
Latest News for BLCO
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of…
Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum, promising product pipelines, and a path toward improved profitability and valuation. BLCO targets 5–7% annual revenue growth through 2028, driven by innovation in contact lenses, dry eye therapies, and premium…
Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bausch + Lomb Corporation (NYSE: BLCO - Get Free Report) shares gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $17.73, but opened at $16.76. Bausch + Lomb shares last traded at $17.2710, with a volume of 263,497 shares traded. The company reported $0.32 earnings per share
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLCO.
U.S. House Trading
No House trades found for BLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.